Biologicals for severe asthma: what we can learn from real-life experiences?

D Bagnasco, M Caminati… - Current Opinion in …, 2020‏ - journals.lww.com
Biologicals for severe asthma: what we can learn from real-l... : Current Opinion in Allergy and
Clinical Immunology Biologicals for severe asthma: what we can learn from real-life experiences …

[HTML][HTML] Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma

G Bölke, X Tong, T Zuberbier, J Bousquet… - World Allergy …, 2022‏ - Elsevier
Background Present guidelines recommend a life-long therapy with mepolizumab in
patients suffering from severe eosinophilic asthma as several studies proved the …

メポリズマブ中止後に重度の末梢神経障害で発症した好酸球性多発血管炎性肉芽腫症の 1 例

川﨑友暉, 田村暁子, 柴田益成, 西中和人, 野里聡子… - 臨床神経学, 2025‏ - jstage.jst.go.jp
抄録 症例は 78 歳男性. 喘息, 副鼻腔炎の治療中, メポリズマブ中止後に喘息が増悪,
急速進行性の四肢運動麻痺および感覚障害が出現した. 血液検査で好酸球増多 …

Skip** a single dose of mepolizumab resulted in significant clinical and functional deterioration.

AI Papaioannou, M Kallieri, S Papiris… - Pneumon, 2020‏ - search.ebscohost.com
Therapy with biologics is now the first choice of add on therapy in the management of severe
asthma. However, little is known about the consequences of poor adherence to therapy on …